LeonaBio

Update in progress

LONA (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

LeonaBio, Inc. is a clinical‑stage biopharmaceutical company developing small molecules to support neuronal health and slow neurodegeneration. Its pipeline includes ATH-1105 for amyotrophic lateral sclerosis and ATH-1020 for neurodegenerative diseases, both in Phase 1, plus early preclinical compounds. Formerly Athira Pharma, the company changed its name to LeonaBio in January 2026. It was founded in 2011 and is based in Bothell, Washington.

Company score

Sentiment: 0.23; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.23; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive